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Association of Antithrombotic Drug Use
With Subdural Hematoma Risk
David Gaist, MD, PhD; Luis Alberto García Rodríguez, MD; Maja Hellfritzsch, MD; Frantz Rom Poulsen, MD, PhD;
Bo Halle, MD, PhD; Jesper Hallas, MD, DrMSc; Anton Pottegård, MScPharm, PhD
IMPORTANCE Incidence of subdural hematoma has been reported to be increasing. To what
extent this is related to increasing use of antithrombotic drugs is unknown.
OBJECTIVES To estimate the association between use of antithrombotic drugs and subdural
hematoma risk and determine trends in subdural hematoma incidence and antithrombotic
drug use in the general population.
DESIGN, SETTING, AND PARTICIPANTS Case-control study of 10010 patients aged 20 to 89
years with a first-ever subdural hematoma principal discharge diagnosis from 2000 to 2015
matched by age, sex, and calendar year to 400 380 individuals from the general population
(controls). Subdural hematoma incidence and antithrombotic drug use was identified using
population-based regional data (population: 484 346) and national data (population:
5.2 million) from Denmark. Conditional logistic regressionmodels were used to estimate
odds ratios (ORs) that were adjusted for comorbidity, education level, and income level.
EXPOSURES Use of low-dose aspirin, clopidogrel, a vitamin K antagonist (VKA), a direct oral
anticoagulant, and combined antithrombotic drug treatment.
MAIN OUTCOMES ANDMEASURES Association of subdural hematomawith antithrombotic
drug use, subdural hematoma incidence rate, and annual prevalence of treatment with
antithrombotic drugs.
RESULTS Among 10010 patients with subdural hematoma (mean age, 69.2 years; 3462
women [34.6%]), 47.3%were taking antithrombotic medications. Current use of low-dose
aspirin (cases: 26.7%, controls: 22.4%; adjusted OR, 1.24 [95% CI, 1.15-1.33]), clopidogrel
(cases: 5.0%, controls: 2.2%; adjusted OR, 1.87 [95% CI, 1.57-2.24]), a direct oral
anticoagulant (cases: 1.0%, controls: 0.6%; adjusted OR, 1.73 [95% CI, 1.31-2.28]), and a VKA
(cases: 14.3%, controls: 4.9%; adjusted OR, 3.69 [95% CI, 3.38-4.03]) were associated with
higher risk of subdural hematoma. The risk of subdural hematomawas highest when a VKA
was used concurrently with an antiplatelet drug (low-dose aspirin and a VKA: 3.6% of cases
and 1.1% of controls; adjusted OR, 4.00 [95% CI, 3.40-4.70]; clopidogrel and a VKA: 0.3%
of cases and 0.04% of controls; adjusted OR, 7.93 [95% CI, 4.49-14.02]). The prevalence of
antithrombotic drug use increased from 31.0 per 1000 individuals from the general
population in 2000 to 76.9 per 1000 individuals in 2015 (P < .001 for trend). The overall
subdural hematoma incidence rate increased from 10.9 per 100000 person-years in 2000
to 19.0 per 100000 person-years in 2015 (P < .001 for trend). The largest increase was
among older patients (>75 years; n = 4441) who experienced an increase from 55.1 per
100000 person-years to 99.7 per 100000 person-years (P < .001 for trend).
CONCLUSIONS AND RELEVANCE In Denmark, antithrombotic drug use was associated with
higher risk of subdural hematoma; and the highest odds of subdural hematomawas
associated with combined use of a VKA and an antiplatelet drug. The increased incidence of
subdural hematoma from 2000 to 2015 appears to be associated with the increased use
of antithrombotic drugs, particularly use of a VKA among older patients.
JAMA. 2017;317(8):836-846. doi:10.1001/jama.2017.0639
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S ubdural hematoma, which is an intracranial hemor-rhage localizedunder theduralmembraneandabovethebrain surface, can be classified into 2 categories: acute
subdural hematomaandsubacuteor chronichematoma.Both
subdural hematoma types are typically traumatic. Acute sub-
dural hematoma is more frequently associated with severe
trauma and usually becomes clinically apparent within 72
hours,whereassubacuteorchronicsubduralhematomaismost
often seen weeks to months after relatively modest trauma
(eg, low-impact falls among elderly individuals).1
Since the 1980s, studieswith data on subacute or chronic
subdural hematoma have reported an increase in the inci-
denceof this disorder in bothEurope and theUnited States.2,3
Subacute or chronic subdural hematoma incidence is pre-
dicted to further increase due to the agingpopulation.2Use of
antithrombotic drugshasbeenassociatedwith increased sub-
acute or chronic subdural hematoma risk. Inmeta-analyses of
controlled trials, use of a vitamin K antagonist (VKA) was as-
sociated with a pooled odds ratio (OR) of 3.0 for subacute or
chronic subdural hematoma compared with antiplatelet
therapy, and use of low-dose aspirin compared with no anti-
thrombotic treatmentwas associatedwith a pooledORof 1.6,
which was not statistically significant.4,5
However, epidemiological data on the association of an-
tithrombotic drug use with subdural hematoma risk are lim-
ited, particularlywith regard to antiplatelet druguse6 anduse
of a direct oral anticoagulant, and in relation to more aggres-
sive regimens ofmultiple antithrombotic drugs,which are in-
creasingly common.7 The purpose of this study was to pro-
videupdatedestimates of subdural hematoma risk associated
with antithrombotic drug use and to explore recent trends in
antithrombotic druguse in relation to subdural hematomaoc-
currence.
Methods
Case-control analyses and descriptive analyses were per-
formedonDanishnationalandregionalpopulation-baseddata.
The studywasapprovedby theDanishDataProtectionAgency
and the Statens Serum Institut. According to Danish law, ap-
proval from an ethics board and informed consent are not re-
quired for register studies.8
Cases
Caseswere patients aged 20 to 89 yearswith a first-ever prin-
cipaldischarge codeof subduralhematoma from2000to2015
according to Danish National Patient Register9 data (dis-
charge, outpatient, procedure, and medication codes appear
ineTable 1 in theSupplement).Thedateof admissionwasused
as the index date. Cases with any history of subdural hema-
toma recordedbefore 2000and individualswith residency in
Denmark for less than 10 consecutive years were excluded.
Controls
Using risk set sampling10 andapplying the sameeligibility and
exclusioncriteria as for cases,40controls fromtheDanishgen-
eralpopulationweresampled toeachcaseviauseof theDanish
CivilRegistrationSystem.11Controlswerematchedbybirthyear
and sex to their index case and were assigned an index date
identical to the event date of their corresponding case.
Assessment of Antithrombotic Drug Exposure, Potential
Confounders, and Short-termMortality
Dataon filledprescriptionswere retrieved fromtheDanishNa-
tional Prescription Registry.12 For each prescription, the date
the drug was dispensed and a full account of the dispensed
product (including theAnatomicalTherapeuticChemical code)
were recorded.13 The indication and prescribed dose are not
available in the prescription registry.
Based on prescriptions dispensed from 1995 up to 1 day
prior to the index date, cases and controls were classified as
ever users (≥1 prescription) or never users (noprescription) of
low-dose aspirin (only available in doses of ≤150 mg in
Denmark), clopidogrel, other adenosine diphosphate inhibi-
tors (prasugrel and ticagrelor), or dipyridamole. The same
principles were applied for an oral anticoagulant drug classi-
fied as a VKA (warfarin or phenprocoumon) and a direct oral
anticoagulant (dabigatran etexilate, rivaroxaban, or apixa-
ban). The assessment of drug exposure is further detailed in
the eMethods in the Supplement.
National register data (population: 5.2million)were used
toclassify individualswith regard toanumberofdisorders that
were potential confounders, which are listed in the statistical
analyses section (codes appear in eTable 1 in the Supple-
ment). As proxies for socioeconomic status, individuals were
classified byhighest education level attained (years of educa-
tion: 7-10 years, 11-12 years, ≥13 years, or missing) and by in-
come level (low, middle, and high according to tertiles of in-
dividual incomes in the control group).8,14 Register data from
the continuously updated Danish Civil Registration System11
were used to ascertain 30-day fatality rates for cases.
Regional Data
Information on certain factors of potential interest (eg, subdu-
ral hematoma type, trauma severity) is not routinely collected
inDanish registers.Therefore, informationwasgatheredonthe
subset of patients with subdural hematoma who were from
the Funen area (population: 484346 in 2009), which has 1 of
the 5 facilities with a neurosurgery department in Denmark.12
Key Points
Question Are changes in subdural hematoma incidence related to
antithrombotic drug use?
Findings In this observational studywith 10010 subdural
hematoma cases and 400380 controls, subdural hematoma risk
was significantly associatedwith antithrombotic drug use, in
particular use of a vitamin K antagonist (adjusted odds ratio, 3.69).
An observed increase in antithrombotic drug usewas related to
an increase in subdural hematoma incidence from 10.9 per 100000
person-years in 2000 to 19.0 per 100000person-years in 2015.
Meaning The increased incidence of subdural hematomawas
associated with increased use of antithrombotic drugs, especially
use of a vitamin K antagonist.
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Patients with verified subdural hematoma (cases) were
classified as having acute subdural hematoma or subacute or
chronic subdural hematoma based on brain scan results ana-
lyzedby2neurosurgeons,whoalsoevaluatedthepresenceand
severity of the head trauma according to medical record in-
formation (eMethods in the Supplement).15 Use of an anti-
thromboticdrugby thevalidatedcasesand their generalpopu-
lation controlswas assessed for the period from2000 to 2012
when data were available.
Statistical Analyses
Conditional logistic regressionwasused to compute adjusted
ORs and 95%CIs for subdural hematoma associatedwith use
of low-dose aspirin, clopidogrel, a VKA, and a direct oral an-
ticoagulant. Because use of other adenosine diphosphate re-
ceptor inhibitors (prasugrel and ticagrelor) was limited dur-
ing the studyperiod, analyses restricted to thisdrugclasswere
not performed.
The analyseswere adjusted for (1) the presence of chronic
obstructive pulmonary disease (as a marker of smoking),
disorders indicative of high intake of alcohol, chronic he-
patic diseases, chronic renal failure, diabetes, myocardial
infarction, angina, unstable angina, peripheral artery disease,
coagulopathy, hypertension, epilepsy, dementia, or stroke;
(2) use of nonsteroidal anti-inflammatory drugs, selective
serotonin reuptake inhibitors, statins, hypnotics and seda-
tives (including benzodiazepines), postmenopausal hormone
replacement therapy, or oral corticosteroids; and (3) highest
education level attained and income level as proxies for
socioeconomic status.
Analyses focusing on any use or use of a single antiplate-
let drug were further adjusted for current use of any oral an-
ticoagulant. Similarly, analyses for use of a single anticoagu-
lant were adjusted for current use of any antiplatelet drug.
Furthermore,because low-doseaspirin isoftenprescribedwith
clopidogrel ordipyridamole, analyses for thesedrugswere ad-
justed for current use of low-dose aspirin and vice versa.
We tested whether the ORs for the different antithrombotic
regimens differed by using a likelihood ratio test, which com-
pared 2models: onemodel in which themain exposure vari-
ablewasuseofanyantithrombotic regimenandanothermodel
in which the individual antithrombotic regimens were speci-
fied. Differences in strength of association between sub-
groups or between different outcomes were evaluated using
the 2-sampleWald test. A 2-sided limit of .05was used as the
significance threshold.
Using the regional data, the association of antithrom-
botic drug use with subdural hematoma stratified by type of
subdural hematoma and head trauma history was assessed.
Using cases only, the association between use of a VKA or use
of low-dose aspirin and imaging characteristics (subdural he-
matoma width, midline structure deviation), surgical treat-
ment, and 30-day mortality, stratified by subdural hema-
toma type was studied. Age and sex were adjusted for using
linear regression (continuous outcomes) or logistic regres-
sion (categorical outcomes). The annual incidence rate of
subdural hematoma was estimated using census data from
Statistics Denmark,16 standardized (age and sex) to the popu-
lation in2008andtested for trend (linear regression;eMethods
in the Supplement).
Regional data on antithrombotic prescriptions for the pe-
riod from 2000 to 2015were retrieved.12 For each antithrom-
botic regimen, thenumber of regional residentswhowereus-
ers of that regimen on a given date was calculated, according
to the exposure definition used in themain study. Using cen-
sus data, the user prevalence proportion for this regimen for
a given day was estimated and hence an average prevalence
proportion for anentire calendar year. These analyseswere re-
stricted to the same age population as in the main analyses
(ie, aged 20-89 years).
Probability results of 2-tailed tests less than .05were con-
sidered statistically significant. All analyses were performed
using Stata SE version 14.1 (StataCorp).
Results
A total of 10 010 incident cases of subdural hematoma
(3462women [34.6%])were identified inDenmarkduring the
study periodwith amean age of 69.2 years (median, 72 years
[interquartile range, 60-81 years]) and 47.3%were taking an-
tithrombotic medications. The 30-day mortality of patients
with subdural hematoma was 16.1%.
Comparedwith400380matchedcontrols,caseshadhigher
levels of comorbidity for the disorders included in the present
analyses, especially illnesses indicative of high intake of alco-
hol (17.6%ofcasesvs4.6%ofcontrols), butalso regardingahis-
toryofhypertension (54.0%vs46.3%), stroke (14.2%vs6.8%),
epilepsy (6.6% vs 1.8%), dementia (5.8% vs 2.7%), chronic re-
nal insufficiency (2.9%vs 1.5%), chronic hepatic disease (2.6%
vs 1.0%), andcoagulopathy (0.5%vs0.2%) (Table 1). Caseshad
less frequently completed 13ormoreyears of education (16.1%
vs 17.9% of controls) and less frequently had high income lev-
els (22.8% vs 33.3% of controls) (Table 1). All abovementioned
comparisons were statistically significant (P < .001).
With the exception of oral corticosteroids and postmeno-
pausal hormone therapy, preadmission medication use was
more prevalent among cases than controls for the drugs in-
cluded in the analyses and for theuseof antithrombotic drugs
(Table 1; P < .001 for both comparisons). The risk of subdural
hematoma was higher with current use of low-dose aspirin
(cases: 26.7%, controls: 22.4%;adjustedOR, 1.24 [95%CI, 1.15-
1.33]), clopidogrel (cases: 5.0%, controls: 2.2%; adjusted OR,
1.87 [95% CI, 1.57-2.24]), a direct oral anticoagulant (cases:
1.0%,controls:0.6%;adjustedOR, 1.73 [95%CI, 1.31-2.28]), and
a VKA (cases: 14.3%, controls: 4.9%; adjusted OR, 3.69 [95%
CI, 3.38-4.03];Table 2 andTable 3). For low-dose aspirin, sub-
dural hematoma riskwas inversely related to duration of cur-
rent use; eg, for a duration of less than 1 month (cases: 1.8%,
controls: 0.8%; adjusted OR, 2.66 [95% CI, 2.20-3.22]) com-
pared with a duration of more than 3 years (cases: 8.1%, con-
trols: 7.9%; adjusted OR, 0.99 [95% CI, 0.88-1.10]) (Table 2).
A similar relationshipwasnotobserved for clopidogrel, for
which the subdural hematoma risk remained fairly constant
(adjustedOR range, 1.46-2.18) andwas independent of the du-
ration of current use (Table 2). The risk of subdural hematoma
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Table 1. Characteristics of CasesWith Incident Subdural Hematoma andGeneral Population Controls
No. (%)a
P Valueb
Cases With
Subdural Hematoma
(n = 10 010)
Controls
(n = 400 380)
Sex
Men 6548 (65.4) 261 920 (65.4)
Women 3462 (34.6) 138 460 (34.6)
Age,
median (IQR), y
72 (61-81) 72 (61-81)
Age group, y
20-64 3166 (31.6) 126 620 (31.6)
65-74 2403 (24.0) 96 120 (24.0)
75-89 4441 (44.4) 177 640 (44.4)
30-d Case
fatality rate
1608 (16.1) NA
Admitted to
neurosurgery
department
7352 (73.4) NA
Type of
surgical
procedure
performed
Burr hole 3912 (39.1) NA
Craniotomy 1495 (14.9) NA
None 4603 (46.0) NA
Index period
2000-2005 2971 (29.7) 118 828 (29.7)
2006-2010 3168 (31.6) 126 720 (31.6)
2011-2015 3871 (38.7) 154 832 (38.7)
Medication use
Low-dose
aspirinc
2676 (26.7) 89 502 (22.4) <.001
Clopidogrelc 500 (5.0) 8755 (2.2) <.001
Other
adenosine
diphosphate
inhibitorsc
25 (0.2) 392 (0.1) <.001
Dipyridamolec 505 (5.0) 12 222 (3.1) <.001
Vitamin K
antagonistc
1427 (14.3) 19 659 (4.9) <.001
Warfarin 1367 (13.7) 18 679 (4.7) <.001
Phenprocoumon 74 (0.7) 1102 (0.3) <.001
Direct oral
anticoagulantc
100 (1.0) 2525 (0.6) <.001
Dabigatran 46 (0.5) 1482 (0.4) .16
Rivaroxaban 36 (0.4) 707 (0.2) <.001
Apixaban 26 (0.3) 412 (0.1) <.001
Non–aspirin
NSAIDsd
2041 (20.4) 72 786 (18.2) <.001
Selective
serotonin
reuptake
inhibitorsd
1728 (17.3) 30 664 (7.7) <.001
Hypnotics
and sedativesd
2724 (27.2) 64 950 (16.2) <.001
Statinsd 2504 (25.0) 85 886 (21.5) <.001
Oral
corticosteroidsd
606 (6.1) 24 082 (6.0) .86
Hormone
replacement
therapyd
585 (5.8) 22 025 (5.5) .14
(continued)
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associated with current use of a direct oral anticoagulant or a
VKA did not vary substantially by duration (Table 3). Limiting
the analyses to individuals with current use of a single anti-
thrombotic drug and no use of other antithrombotic drugs
withinthe last 12months (toexcludepatientswhohadswitched
fromotherantithromboticdrugs)producedriskestimatessimi-
lar to those of the main analyses (eg, low-dose aspirin: ad-
justedOR, 1.19 [95%CI, 1.10-1.19]; clopidogrel: adjustedOR, 1.61
[95% CI, 1.30-1.98]) (eTable 2 in the Supplement).
Furthermore, limiting theanalyses to individualswith first-
time use of antithrombotic drugs (definition appears in the
eMethods in theSupplement) resulted inanadjustedORof 1.39
(95%CI, 1.26-1.52) for low-dose aspirin and an adjustedORof
1.68 (95%CI, 1.31-2.16) for clopidogrel (eTable 3 in the Supple-
ment). These estimates did not change notably when first-
timeusewas further restricted tosingleuseof thedrug inques-
tion (ie, no concomitantuseof other antithromboticdrug) and
corresponded to an adjustedOR of 1.37 (95%CI, 1.24-1.52) for
low-dose aspirin and an adjusted OR of 1.60 (95% CI, 1.21-
2.12) for clopidogrel. For oral anticoagulant drugs, limiting
analyses to first-time use was related to association esti-
mates comparable with those found in the main analyses
(eTable 3 in the Supplement).
The risk of subdural hematoma associated with concur-
rent use of antithrombotic drugs varied across regimens. The
lowest riskwas associatedwith concurrent use of low-dose as-
pirin and dipyridamole (cases: 4.2%, controls: 2.6%; adjusted
OR, 1.17 [95% CI, 0.99-1.38]), whereas the risk of subdural he-
matomawas highest when a VKAwas used concurrently with
anantiplateletdrug (low-doseaspirin andaVKA:3.6%of cases
and 1.1% of controls; adjusted OR, 4.00 [95% CI, 3.40-4.70];
clopidogrel andaVKA:0.3%ofcasesand0.04%ofcontrols; ad-
justed OR, 7.93 [95% CI, 4.49-14.02]) (likelihood ratio test for
overall difference in effect estimates, P < .001; Figure 1).
The observed associations between use of antithrom-
botic drugs and subdural hematoma were stronger among
women than men for use of low-dose aspirin (P = .004) and
a VKA (P < .001) (eTable 4 in the Supplement). Associations
didnot vary substantiallywithin age groupswithuse of clopi-
dogrel, a VKA, and a direct oral anticoagulant, whereas the
association increasedwithuseof low-dose aspirin fromanad-
justed OR of 1.08 (95% CI, 0.90-1.30) for those aged 20 to 64
years toanadjustedORof 1.46 (95%CI, 1.33-1.60) for thoseaged
75 to 89 years (P = .003; eTable 4 in the Supplement).
Inaddition,antithromboticusecarriedagreater riskfor fatal
(died within 30 days of diagnosis) than nonfatal subdural
Table 1. Characteristics of CasesWith Incident Subdural Hematoma andGeneral Population Controls (continued)
No. (%)a
P Valueb
Cases With
Subdural Hematoma
(n = 10 010)
Controls
(n = 400 380)
Comorbidity
Hypertension 5408 (54.0) 185 272 (46.3) <.001
Stroke 1420 (14.2) 27 311 (6.8) <.001
Epilepsy 664 (6.6) 7131 (1.8) <.001
Dementia 582 (5.8) 10 855 (2.7) <.001
Chronic obstructive
pulmonary disease
759 (7.6) 25 027 (6.3) <.001
Diabetes 1264 (12.6) 36 548 (9.1) <.001
Chronic renal
insufficiency
292 (2.9) 5932 (1.5) <.001
Chronic hepatic
disease
256 (2.6) 3913 (1.0) <.001
Coagulopathy 53 (0.5) 746 (0.2) <.001
High intake
of alcohol
1762 (17.6) 18 382 (4.6) <.001
Myocardial infarction 856 (8.6) 27 630 (6.9) <.001
Unstable angina 335 (3.3) 9486 (2.4) <.001
Other angina 1303 (13.0) 41 467 (10.4) <.001
Peripheral artery
disease
251 (2.5) 7962 (2.0) <.001
Education level, y
7-10 4073 (40.7) 154 584 (38.6) <.001
11-12 3529 (35.3) 143 705 (35.9) .19
≥13 1611 (16.1) 71 609 (17.9) <.001
Missing 797 (8.0) 30 482 (7.6) .19
Income levele
Low 4832 (48.3) 133 455 (33.3) <.001
Middle 2892 (28.9) 133 467 (33.3) <.001
High 2286 (22.8) 133 458 (33.3) <.001
Abbreviations: IQR, interquartile
range; NA, data not provided because
not relevant; NSAID, nonsteroidal
anti-inflammatory drug.
a Data are expressed as No. (%)
unless otherwise indicated. Data
are fromDenmark from 2000
through 2015.
bCalculated using the χ2 test. Values
not provided for age, sex, and index
year because cases were matched
to controls for these variables.
c Use of drug at index date.
dUse of drug between 1 year and 1
month prior to index date.
e Median annual income
among controls was kr 69 342
(IQR, kr 29 654-kr 98 372) in the
low income level, kr 157 418
(IQR, kr 141 850-kr 172 563) in the
middle income level, and kr 268 155
(IQR, kr 224 700-kr 341 543) in the
high income level. One krone equals
approximately US $0.15.
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hematoma.Thispatternwasmostpronouncedwithuseofadi-
rectoral anticoagulant (fatal subduralhematoma:adjustedOR,
3.87[95%CI,1.84-8.13]vsnonfatalsubduralhematoma:adjusted
OR, 1.44 [95%CI, 1.05-1.96];P = .01) andaVKA (fatal: adjusted
OR,6.30[95%CI,5.04-7.88]vsnonfatal: adjustedOR,3.33 [95%
CI, 3.02-3.67]; P < .001) (eTable 4 in the Supplement).
The regionaldata fromtheFunenarea comprised936vali-
dated caseswith amedian ageof 72 years (interquartile range,
59-81 years) and 34.5% females. Based on visual assessment
of brain imaging studies, 55% of validated subdural hema-
tomacaseswere classified as subacuteor chronic subdural he-
matoma and 45% as acute subdural hematoma.15 Results of
analyses of associations with antithrombotic drug use based
exclusively on these validated cases and their 18689 controls
were highly similar to estimates derived from the nationwide
data (eTable 5 in the Supplement).
Currentuseof low-doseaspirinwasnotassociatedwithrisk
of subacute or chronic subdural hematoma (adjusted OR, 1.10
[95%CI,0.83-1.45]),whereastherewasahigherriskofacutesub-
duralhematoma (adjustedOR, 1.47 [95%CI, 1.04-2.08]; eTable
6 in the Supplement). In contrast, current use of a VKAwas as-
sociatedwith higher risk of both subacute or chronic subdural
hematoma(adjustedOR,2.59[95%CI,1.88-3.55])andacutesub-
dural hematoma (adjustedOR, 4.72 [95%CI, 3.31-6.72]).
Analyses limited to 650 cases with trauma of known se-
verity (definition of trauma severity appears in eMethods in
the Supplement) showed that current use of antithrombotic
drugs was associated with subdural hematoma in the low to
moderate trauma severity group (low-dose aspirin: adjusted
OR, 1.41 [95%CI, 1.04-1.92]; aVKA: adjustedOR, 3.51 [95%CI,
2.51-4.89]). In the severe trauma group, use of a VKA pre-
sented the strongest association with risk of subdural hema-
toma (adjusted OR, 2.49 [95% CI, 1.31-4.73]), whereas low-
dose aspirin was not associated with higher risk of subdural
hematoma (adjusted OR, 0.93 [95%CI, 0.53-1.63]; eTable 7 in
the Supplement).
Table 2. Use of Antiplatelet Drugs and Risk of Subdural Hematoma in Denmark, 2000-2015
No. (%)
Adjusted OR
(95% CI)a
Adjusted OR
(95% CI)b
Cases With Subdural Hematoma
(n = 10 010)
Controls
(n = 400 380)
Never use of any antithrombotic drug 5013 (50.1) 252 593 (63.1) 1 [Reference] 1 [Reference]
Low-dose aspirin usec
Everd 4204 (42.0) 132 727 (33.2) 1.83 (1.75-1.92) 1.20 (1.13-1.27)
Current 2676 (26.7) 89 502 (22.4) 1.72 (1.63-1.82) 1.24 (1.15-1.33)
Recent 228 (2.3) 5170 (1.3) 2.43 (2.10-2.80) 1.39 (1.15-1.68)
Past 295 (2.9) 7239 (1.8) 2.34 (2.06-2.65) 1.14 (0.94-1.38)
Distant 1005 (10.0) 30 816 (7.7) 1.86 (1.73-2.01) 1.03 (0.93-1.14)
Duration of current use
<1 mo 185 (1.8) 3127 (0.8) 3.44 (2.93-4.03) 2.66 (2.20-3.22)
≥1-≤3 mo 217 (2.2) 6142 (1.5) 2.01 (1.74-2.32) 1.41 (1.17-1.68)
>3-≤12 mo 695 (6.9) 21 135 (5.3) 1.84 (1.69-2.00) 1.26 (1.12-1.41)
>1-≤3 y 767 (7.7) 27 423 (6.8) 1.59 (1.46-1.73) 1.09 (0.98-1.22)
>3 y 812 (8.1) 31 675 (7.9) 1.50 (1.38-1.63) 0.99 (0.88-1.10)
Clopidogrel usec
Everd 890 (8.9) 21 694 (5.4) 2.45 (2.26-2.66) 1.75 (1.50-2.04)
Current 500 (5.0) 8755 (2.2) 3.46 (3.11-3.84) 1.87 (1.57-2.24)
Recent 29 (0.3) 654 (0.2) 2.39 (1.62-3.53) 1.53 (0.77-3.05)
Past 48 (0.5) 1589 (0.4) 1.66 (1.23-2.23) 1.13 (0.60-2.13)
Distant 313 (3.1) 10 696 (2.7) 1.76 (1.55-1.99) 1.26 (0.92-1.71)
Duration of current use
<1 mo 28 (0.3) 455 (0.1) 3.65 (2.42-5.49) 1.46 (0.70-3.05)
≥1-≤3 mo 71 (0.7) 909 (0.2) 4.47 (3.43-5.81) 2.18 (1.37-3.47)
>3-≤12 mo 176 (1.8) 3047 (0.8) 3.46 (2.93-4.09) 1.78 (1.36-2.32)
>1-≤3 y 157 (1.6) 2919 (0.7) 3.18 (2.67-3.80) 1.71 (1.32-2.22)
>3 y 68 (0.7) 1425 (0.4) 2.85 (2.20-3.71) 1.49 (1.05-2.13)
Abbreviation: OR, odds ratio.
a Adjusted for age, sex, and calendar period (year) by design.
bAdjusted for age, sex, and calendar period (by design) and based on register
data for presence of hypertension, stroke, epilepsy, dementia, chronic
obstructive pulmonary disease, high intake of alcohol, chronic hepatic disease,
chronic renal insufficiency, diabetes, myocardial infarction, angina, unstable
angina, peripheral artery disease; use of an oral anticoagulant, nonsteroidal
anti-inflammatory drug, selective serotonin reuptake inhibitor, hypnotic and
sedative, hormone replacement therapy, or oral corticosteroid drug; and
socioeconomic status (education level and income level). Analyses for
low-dose aspirin were adjusted for current use of clopidogrel and vice versa.
c Based on themost recent treatment episode prior to the index date (date of
diagnosis for cases and date of selection for controls), exposure was divided
into current use (at index date), recent use (treatment episode ending 1-90
days before index date), past use (91-365 days before index date), and distant
use (>365 days before index date).
d Previous or concurrent use of other antiplatelet drugs included.
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Analyses restricted to validated cases revealed that cur-
rent users of VKAs were more likely to exhibit midline struc-
ture deviation on their brain scan (subacute or chronic sub-
dural hematoma: OR, 3.29 [95%CI, 1.14-9.51]; acute subdural
hematoma: OR, 2.80 [95% CI, 1.18-6.60]; eTable 8 in the
Supplement) and had higher 30-day mortality (subacute or
chronic subdural hematoma: OR, 2.77 [95% CI, 0.94-8.18];
acute subdural hematoma, 1.33 [95% CI, 0.62-2.89]; eTable 9
in the Supplement) compared with never users of anticoagu-
lants. Current low-dose aspirin use resulted in far lessmarked
differenceswith regard to theseoutcomes (eTable8andeTable
9 in the Supplement).
The incidenceof subduralhematoma increasedduring the
studyperiod from10.9per 100000person-years (95%CI, 9.9-
12.0per 100000person-years) in2000 (441 cases in4036965
person-years) to 19.0 per 100000person-years (95%CI, 17.8-
20.4per 100000person-years) in 2015 (819 cases in 4 301 391
person-years) (P < .001 for trend). The largest increase in the
incidence of subdural hematoma occurred among older pa-
tients (aged 75-89 years; n = 4441) and went from 55.1 per
100000 person-years (191 cases in 346529 person-years) to
99.7 per 100000 person-years (382 cases in 383030 person-
years) (P < .001 for trend). The corresponding incidence trend
among men aged 75 to 89 years increased from 77.9 per
100000person-years (95%CI, 63.5-94.6per 100000person-
years) in 2000 (102 cases in 130899person-years) to 135.5 per
100000person-years (95%CI, 118.3-154.6per 100000person-
years) in 2015 (222 cases in 163 778 person-years) (P < .001;
Figure 2 and eTable 10 in the Supplement).
The regional analyses revealed increases in antithrom-
boticdruguseduring the studyperiodbothas singledrug regi-
mens (average prevalence proportion of 31.0 per 1000 inhabi-
tants from the general population in 2000 vs 76.9 per 1000
inhabitants in2015;P < .001 for trend)andconcurrentdruguse
regimens (averageprevalenceproportionof2.6per 1000inhab-
itants in 2000 vs 17.3 per 1000 inhabitants in 2015, P < .001;
Figure 3). Anyuseof aVKA increased from7.4per 1000 inhab-
itants in 2000 to 16.7 per 1000 inhabitants in 2015 (P < .001).
Table 3. Use of an Oral Anticoagulant and Risk of Subdural Hematoma in Denmark, 2000-2015
No. (%)
Adjusted OR
(95% CI)a
Adjusted OR
(95% CI)b
Cases With Subdural Hematoma
(n = 10 010)
Controls
(n = 400 380)
Never use of any antithrombotic drug 5013 (50.1) 252 593 (63.1) 1 [Reference] 1 [Reference]
Direct oral anticoagulant usec
Ever 170 (1.7) 4423 (1.1) 2.34 (1.96-2.79) 1.88 (1.51-2.32)
Current 100 (1.0) 2525 (0.6) 2.50 (1.99-3.13) 1.73 (1.31-2.28)
Recent 8 (0.008) 241 (0.1) 2.01 (0.97-4.18) 2.00 (0.83-4.78)
Past 16 (0.2) 470 (0.1) 2.08 (1.24-3.50) 1.91 (0.98-3.70)
Distant 46 (0.5) 1187 (0.3) 2.39 (1.74-3.28) 2.69 (1.85-3.92)
Duration of current use
<1 mo 16 (0.2) 234 (0.1) 4.22 (2.43-7.33) 2.41 (1.07-5.44)
≥1-≤3 mo 22 (0.2) 391 (0.1) 3.49 (2.19-5.56) 2.98 (1.69-5.27)
>3-≤12 mo 33 (0.3) 956 (0.2) 2.20 (1.51-3.20) 1.41 (0.89-2.22)
>1-≤3 y 25 (0.2) 815 (0.2) 2.00 (1.31-3.06) 1.61 (1.01-2.56)
>3 y 4 (0.004) 129 (0.003) 1.66 (0.59-4.68) 0.81 (0.19-3.49)
Vitamin K antagonist usec
Ever 1890 (18.9) 33 431 (8.3) 3.42 (3.21-3.64) 2.83 (2.61-3.06)
Current 1427 (14.3) 19 659 (4.9) 4.43 (4.13-4.75) 3.69 (3.38-4.03)
Recent 85 (0.8) 1320 (0.3) 3.62 (2.86-4.58) 2.71 (2.01-3.67)
Past 88 (0.9) 1966 (0.5) 2.67 (2.13-3.35) 1.57 (1.12-2.20)
Distant 290 (2.9) 10 486 (2.6) 1.64 (1.44-1.86) 1.18 (0.97-1.43)
Duration of current use
<1 mo 75 (0.7) 938 (0.2) 4.42 (3.43-5.71) 3.18 (2.27-4.45)
≥1-≤3 mo 165 (1.6) 1804 (0.5) 5.25 (4.39-6.27) 4.59 (3.65-5.78)
>3-≤12 mo 378 (3.8) 4923 (1.2) 4.58 (4.06-5.16) 3.70 (3.16-4.32)
>1-≤3 y 368 (3.7) 4979 (1.2) 4.26 (3.78-4.80) 3.42 (2.94-3.99)
>3 y 441 (4.4) 7015 (1.8) 3.87 (3.46-4.32) 3.28 (2.85-3.77)
Abbreviation: OR, odds ratio.
a Adjusted for age, sex, and calendar period (year) by design.
bAdjusted for age, sex, and calendar period (by design) and based on register
data for presence of hypertension, stroke, epilepsy, dementia, chronic
obstructive pulmonary disease, high intake of alcohol, chronic hepatic disease,
chronic renal insufficiency, diabetes, myocardial infarction, angina, unstable
angina, peripheral artery disease; use of antiplatelet drugs, nonsteroidal
anti-inflammatory drugs, selective serotonin reuptake inhibitors, hypnotics
and sedatives, hormone replacement therapy, or oral corticosteroid drugs;
and socioeconomic status (education level and income level).
c Based on themost recent treatment episode prior to the index date (date of
diagnosis for cases and date of selection for controls), exposure was divided
into current use (at index date), recent use (treatment episode ending 1-90
days before index date), past use (91-365 days before index date), and distant
use (>365 days before index date).
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Thirty-day mortality after subdural hematoma diagnosis
declinedduringthestudyperiodfrom17.9%in2000-2004(432
of 2414 patients died) to 13.1% in 2013-2015 (314 of 2395 pa-
tientsdied).However, thedecline in30-daymortalityover time
was only observed for patients aged 20 to 64 years and aged
65 to 74years (P < .001 for trend for both agegroups),whereas
the 30-day mortality remained stable for patients aged 75 to
89 years (P = .40 for trend; eFigure 1 in the Supplement). Nei-
ther this measure of short-time mortality, nor the annual in-
cidence rate estimates werematerially changed after age and
sex standardization (eFigure 2 in the Supplement).
Discussion
In this case-control study that included 10010 patients with
subdural hematoma, low-dose aspirin was associated with a
small risk, use of clopidogrel and a direct oral anticoagulant
with a moderate risk, and use of a VKA with a higher risk of
subdural hematoma. With the exception of low-dose aspirin
combinedwithdipyridamole,whichwasassociatedwitha risk
similar to low-dose aspirinmonotherapy, concomitant use of
more than 1 antithrombotic drug was related to substantially
highersubduralhematomarisk,whichwasparticularlymarked
for combined treatmentof clopidogrelwithaVKA.Antithrom-
botic drug use was found to be associated with higher rela-
tive risks of subdural hematoma in women than in men, and
fatal subdural hematoma was more strongly associated with
antithrombotic drug use than nonfatal subdural hematoma.
Incidenceof subduralhematoma,particularlyamongolder
patients (aged75-89years), increasedwithin the 16-year study
period. This observation appears to be temporally related to a
major increase in the use of antithrombotic drugs and in par-
ticular in the use of a VKA. The present data add 1more piece
Figure 2. Incidence Rate of Subdural Hematoma by Sex and Age Group in Denmark, 2000-2015
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Figure 1. Current Use of Antithrombotic Drugs and Risk of Subdural Hematoma
No. (%)
Cases With
Subdural
Hematoma Controls
Adjusted OR
(95% CI)
5013 (50.1) 252 593 (63.1)Never use of antithrombotic drugs 1 [Reference]
Current single antithrombotic drug use
Current dual antithrombotic drug use
Current triple antithrombotic drug use
1665 (16.6) 70 455 (17.6)Low-dose aspirin 1.20 (1.11-1.29)
282 (2.8) 5315 (1.3)Clopidogrel 1.80 (1.49-2.18)
26 (0.3) 171 (0.04)Clopidogrel and vitamin K antagonist 7.93 (4.49-14.02)
64 (0.6) 1978 (0.5)Direct oral anticoagulant 1.55 (1.16-2.09)
1000 (10.0) 14 492 (3.6)Vitamin K antagonist 3.63 (3.31-3.98)
12 (0.1) 137 (0.03)Low-dose aspirin, clopidogrel, and vitamin K antagonist 4.25 (2.07-8.72)
421 (4.2) 10 521 (2.6)Low-dose aspirin and dipyridamole 1.17 (0.99-1.38)
151 (1.5) 2810 (0.7)Low-dose aspirin and clopidogrel 2.45 (1.89-3.19)
13 (0.1) 324 (0.1)Low-dose aspirin and direct oral anticoagulant 2.52 (1.33-4.77)
356 (3.6) 4539 (1.1)Low-dose aspirin and vitamin K antagonist 4.00 (3.40-4.70)
20101.0
Adjusted OR (95% CI)
Error bars indicate 95% CIs; OR, odds ratio. The data were adjusted for age, sex, calendar period, comorbidity, education level, and income level.
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Figure 3. Use of Antithrombotic Regimens per 1000 Inhabitants in a GeographicallyWell-Defined Part
of Denmark
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Only those aged 20 to 89 years
(n = 363000) were included.
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of evidence to the complex risk-benefit equationof antithrom-
boticdruguse. It isknownthat thesedrugs result innetbenefits
overall inpatientswithcleartherapeutic indications.17-19Further-
more, thepresent results are in linewithprevious studies indi-
catinga lowerriskof intracranialhemorrhageinassociationwith
useofadirectoralanticoagulantcomparedwithuseofaVKA.20,21
Although use of antithrombotic drugs has long been rec-
ognizedas a risk factor for subduralhematoma,previous stud-
ies were either based exclusively on patients with subdural
hematoma (ie, with no comparison group)22-25 or focused ex-
clusively on patients treated with an anticoagulant.26,27 In a
case-control study from Italy with 345 cases of subacute or
chronic subdural hematoma collected from a single hospital
andmatched to 138786emergencydepartment attendees, an-
tithrombotic drug use increased subacute or chronic subdu-
ral hematoma risk (anticoagulant use: OR, 2.46 [95%CI, 1.66-
3.64]; antiplatelet drug use: OR, 1.42 [95% CI, 1.07-1.89]).6
Meta-analyses of randomized clinical trials reported similar,
albeit slightly higher estimates of the risk of subdural hema-
tomaconferredbyuseof aVKAor low-dose aspirin.4,5Despite
differences in setting and design, the present results are thus
in line with previous studies.
InanationwideSwedish register-basedstudyspanning the
period of 1987 to 2010, subdural hematomawas themost fre-
quent traumatic intracranial injury (excludingconcussion), and
the proportion of patients with subdural hematoma increased
substantially over time.3 A study from the United States also
showedanincrease inthe incidenceratesofsubacuteorchronic
subdural hematoma, and the researchers predicted that sub-
acuteorchronicsubduralhematomawillbecomethemostcom-
mon cranial neurosurgical condition among adults in 2030.2
Steep increases in incidenceratesofsubduralhematomaamong
olderpatients(aged75-89years)werefoundinthepresentstudy.
Furthermore, the present results emphasize that thema-
jor shifts inpatternsof antithromboticdrug treatment forolder
individuals,28 and the increasing use of more aggressive an-
tithrombotic regimens,havealreadyhadamajor effectonsub-
dural hematoma incidence. Thepresent resultsmaypartly be
drivenby increasingly rapidandeasier access tobrain imaging.
However, if this was predominantly the case, a decrease in
short-termmortality over time would have been expected as
a consequence of less severe cases being detected inmore re-
cent years. Indeed, this seems to be the case for patients aged
20 to 74 years.
However, the 30-daymortality rate remained stable in pa-
tients aged 75 to 89 years, which is the age group with use of
antithrombotic drugs that was markedly more prevalent than
that of younger age groups. Increasing surveillance is unlikely
toexplain the increasing incidence ratesof subduralhematoma
other than fora fractionof thepresent findings.A lower thresh-
old for scanning patientswho are taking antithrombotic drugs
could also result inhigher detection rates of less severe subdu-
ralhematomacasesandbias the results.However,basedonthe
presentstudydataonimagingcharacteristics,treatment,andout-
come among validated cases, this scenario is unlikely.
The notion that trauma events couldmodify the effect of
antithrombotic use6 is supported by thepresent results based
on regional data. Risk estimates for preadmission antithrom-
botic drug use were higher among patients with low to mod-
erateseverity traumacomparedwith thosewithsevere trauma.
Although based on small numbers, these results are compat-
ible with antithrombotic drugs playing a greater role in pre-
disposed patients (eg, due to age-related brain atrophy) with
ahistory ofmild tomoderate head trauma comparedwithpa-
tients experiencing a severe head trauma for whom there is
little role left for additional risk factors. This finding is impor-
tant from a public health perspective because the risk of ex-
periencinga small tomoderatehead traumaexceeds theprob-
ability of experiencing a severe head injury.
The present study has a number of strengths. The study
wasperformed inDenmark, a settingwith freeaccess tohealth
services, independent of income level. Population-based reg-
isterswereusedwithcomplete coverageandcontinuously col-
lected data on all Danish residents, an approach that elimi-
natedrecallbiasandminimizedselectionbias. Ithaspreviously
been shown that the subdural hematoma code used to iden-
tify cases in this study is highly valid with a positive predic-
tive value of 96%.15
This study has several limitations. Even though the ap-
proachused in this study enabled the identificationof subdu-
ral hematoma incident cases withminimal misclassification,
it probably resulted in incomplete coverage. Based on the re-
sults fromaprevious validation study, the incidence rates are
probably underestimated by approximately 22%.15 Also, the
small numbersprevented the assessmentof the associationof
individual typesofdirect oral anticoagulantsdrugs, orof other
adenosine diphosphate receptor inhibitor use with subdural
hematoma risk. Low-dose aspirin is the only antiplatelet drug
inDenmark that isavailableover-the-counter.Because thecov-
erage of the prescription registry for low-dose aspirin is in the
order of 91%,29misclassification of exposure caused by over-
the-counter use of this drug is believed to be ofminor signifi-
cance. Other potential limitations of the present study in-
clude the lack of data on international normalized ratio and
alcohol consumption.
Among patients using a VKA, subdural hematoma risk is
known to be associated with international normalized ratio
levels.30 Information on this factor was lacking, and the ef-
fect of the international normalized ratio on subdural hema-
tomariskcould thereforenotbeassessed.Alcoholoveruse, and
its negative effect on brain volume and associated increased
risk of trauma, predisposes individuals to subdural hema-
toma. In thenationwide study, register-based informationwas
used to assess this effect modifier and possible confounder,
which may have led to considerable misclassification. It is
noted, however, that the estimate of patients with subdural
hematoma and high alcohol intake in the nationwide sample
(17.6%) in the present study was comparable with the frac-
tion of patientswith subdural hematoma classifiedwith alco-
holism (16.6%) in the validation study.15
Furthermore, a higher frequency of other disorders pre-
disposing individuals to brain atrophy and associatedwith an
increased riskof falling (eg, dementia)was foundamongcases
compared with controls in the present study. Although ad-
justed for in multivariate analyses, residual confounding by
these and other potential confounders cannot be ruled out.
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Conclusions
In Denmark, antithrombotic drug use was associated with
higher riskof subduralhematoma;andthehighestoddsof sub-
dural hematomawas associated with combined use of a VKA
and an antiplatelet drug. The increased incidence of subdural
hematoma from 2000 to 2015 appears to be associated with
the increased use of antithrombotic drugs, particularly use of
a VKA among older patients.
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